News | November 16, 2022
Cadila recognized for its contribution to leprosy treatment
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
The CDCCs are strategically positioned in regions identified as high-impact areas
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Anandiben Patel, Governor, Uttar Pradesh will inaugurate the two-day celebrations
We must try to make the health care system more accessible for people with disabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Subscribe To Our Newsletter & Stay Updated
